Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

Therapeutic area

Neoplasms benign, malignant and unspecified (incl cysts and polyps) – page 73

  • 3 926 clinical trials
  • 1 543 recruiting
  • 706 conditions
  • 31 countries

Conditions in this area

706 conditions with trials, the busiest first

Non-small cell lung cancer332Breast cancer170Plasma cell myeloma164Neoplasm158Acute myeloid leukaemia132Neoplasm malignant129Colorectal cancer metastatic106Prostate cancer102Colorectal cancer90Ovarian cancer90Hepatocellular carcinoma89Breast cancer metastatic84Non-small cell lung cancer metastatic82Chronic lymphocytic leukaemia80Malignant melanoma79Triple negative breast cancer69Squamous cell carcinoma of head and neck68Hormone receptor positive HER2 negative breast cancer62Non-small cell lung cancer stage IV59Pancreatic carcinoma57Hormone-refractory prostate cancer56Bladder cancer55Gastric cancer55Endometrial cancer53+682

Clinical trials in Neoplasms benign, malignant and unspecified (incl cysts and polyps)

3 926 trials across Europe, recruiting first

Type of trial
Recruitment status
Quick filters

3 926 clinical trials

Otitis media+1

Recruiting

Study on Dupilumab for Patients with Chronic Rhinosinusitis with Nasal Polyps and Eosinophilic Otitis Media

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Dupilumab
  • Sponsor:Amsterdam UMC Stichting

Small cell lung cancer extensive stage

Recruiting

Study of Ifinatamab Deruxtecan with Atezolizumab and Carboplatin for Patients with Extensive-Stage Small Cell Lung Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Atezolizumab
  • Sponsor:Daiichi Sankyo Inc.

Small cell lung cancer

Recruiting

Study on Ifinatamab Deruxtecan and Topotecan for Patients with Relapsed Small Cell Lung Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Topotecan
  • Sponsor:Daiichi Sankyo Inc.

Hepatocellular carcinoma

Recruiting

Study of Fecal Microbiota Transplantation combined with atezolizumab and bevacizumab in patients with unresectable liver cancer who progressed after initial treatment

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Ascorbic Acid
  • Sponsor:Azienda Ospedaliero-Universitaria Di Bologna IRCCS Istituto Di Ricerca E Di Cura A Carattere Scientifico

Colorectal cancer metastatic

Recruiting

Study on Bevacizumab-Based Chemotherapy for Patients with Unresectable Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Centre Hospitalier Regional Universitaire De Tours

Breast cancer metastatic+3

Recruiting

Study on the Impact of Exercise and Atorvastatin on Advanced Breast, Ovarian, Prostate, and Kidney Cancer Patients

Registered drugNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:Atorvastatin
  • Sponsor:Pirkanmaan hyvinvointialue

Pancreatic carcinoma

Recruiting

Study on the Effectiveness of [18F]FAPI-74 PET/CT for Detecting Lymph Node Spread in Patients with Pancreatic Cancer

InvestigationalNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:[Al[18F]F]Fapi-74
  • Sponsor:Turku University Hospital

Non-small cell lung cancer

Recruiting

Study of Sacituzumab and Zimberelimab for Patients with Resectable Non-Small Cell Lung Cancer After Surgery Without Complete Disease Clearance

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Zimberelimab
  • Sponsor:Fundacion GECP

Colon cancer

Recruiting

Study of 18F-FAPI-74 PET/CT Imaging for Detection of Lymph Node Metastases in Patients with Colon Cancer

InvestigationalNo placebo
Countries:FinlandFinland
  • Participants:18–64 years · 65+ years
  • Substances:[Al[18F]F]Fapi-74
  • Sponsor:Turku University Hospital

Neuroendocrine tumour+6

Recruiting

Study of 64Cu-DOTATATE and 18F-FDG PET/CT imaging to predict disease progression in patients with neuroendocrine neoplasms

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Dotatate
  • Sponsor:Rigshospitalet

Chronic lymphocytic leukaemia

Recruiting

Study on Acalabrutinib, Obinutuzumab, and Venetoclax for Untreated High-Risk Chronic Lymphocytic Leukemia Patients

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:University Of Cologne

Neoplasm malignant

Recruiting

Study on the Effectiveness of Tepotinib and Drug Combination for Patients with Advanced Cancer

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Alpelisib
  • Sponsor:Oslo University Hospital HF

Substances studied in this area

The therapies tested most often in Neoplasms benign, malignant and unspecified (incl cysts and polyps) trials.

Pembrolizumab467 clinical trialsCarboplatin344 clinical trialsCisplatin288 clinical trialsPaclitaxel266 clinical trialsFluorouracil239 clinical trialsOxaliplatin230 clinical trialsNivolumab218 clinical trialsDexamethasone169 clinical trialsDurvalumab163 clinical trials
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.